Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Beam Therapeutics (BEAM) FCF Margin: 2019-2025

Historic FCF Margin for Beam Therapeutics (BEAM) over the last 6 years, with Sep 2025 value amounting to -891.83%.

  • Beam Therapeutics' FCF Margin fell 26318.00% to -891.83% in Q3 2025 from the same period last year, while for Sep 2025 it was -632.59%, marking a year-over-year decrease of 59101.00%. This contributed to the annual value of -560.77% for FY2024, which is 51234.00% down from last year.
  • Per Beam Therapeutics' latest filing, its FCF Margin stood at -891.83% for Q3 2025, which was up 5.13% from -940.07% recorded in Q2 2025.
  • In the past 5 years, Beam Therapeutics' FCF Margin ranged from a high of 2,409.68% in Q1 2022 and a low of -834,266.67% during Q1 2021.
  • For the 3-year period, Beam Therapeutics' FCF Margin averaged around -705.43%, with its median value being -628.65% (2024).
  • As far as peak fluctuations go, Beam Therapeutics' FCF Margin tumbled by 39,178,333bps in 2021, and later spiked by 83,667,634bps in 2022.
  • Beam Therapeutics' FCF Margin (Quarterly) stood at -22.59% in 2021, then plummeted by 36,395bps to -386.54% in 2022, then soared by 42,813bps to 41.58% in 2023, then plummeted by 30,544bps to -263.86% in 2024, then crashed by 26,318bps to -891.83% in 2025.
  • Its FCF Margin stands at -891.83% for Q3 2025, versus -940.07% for Q2 2025 and -1,431.71% for Q1 2025.